AR022647A1 - Proceso para preparar una formulacion de liberacion sostenida - Google Patents

Proceso para preparar una formulacion de liberacion sostenida

Info

Publication number
AR022647A1
AR022647A1 ARP000104254A ARP000104254A AR022647A1 AR 022647 A1 AR022647 A1 AR 022647A1 AR P000104254 A ARP000104254 A AR P000104254A AR P000104254 A ARP000104254 A AR P000104254A AR 022647 A1 AR022647 A1 AR 022647A1
Authority
AR
Argentina
Prior art keywords
sustained release
prepare
release formulation
compound
lgt
Prior art date
Application number
ARP000104254A
Other languages
English (en)
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Publication of AR022647A1 publication Critical patent/AR022647A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta se refiere a un proceso para preparar un complejo de liberacion sostenida, el Compuesto (I), que comprende al Compuesto (A), que tiene la formula (A).Y un copolímero que comprende al ácido poli-(1)-láctico-glicolico-tartárico (P(1)LGT), donde elgrupo amino del Compuesto (A) está ionicamente enlazado a ungrupo carboxilo del P(1)LGT.
ARP000104254A 1999-08-18 2000-08-17 Proceso para preparar una formulacion de liberacion sostenida AR022647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE19990700A IES990700A2 (en) 1999-08-18 1999-08-18 Process to make a sustained release formulation

Publications (1)

Publication Number Publication Date
AR022647A1 true AR022647A1 (es) 2002-09-04

Family

ID=11042112

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104254A AR022647A1 (es) 1999-08-18 2000-08-17 Proceso para preparar una formulacion de liberacion sostenida

Country Status (26)

Country Link
US (1) US6893645B1 (es)
EP (1) EP1212095B1 (es)
JP (1) JP3730917B2 (es)
CN (2) CN1823736A (es)
AR (1) AR022647A1 (es)
AT (1) ATE243044T1 (es)
AU (1) AU755229B2 (es)
BR (1) BR0013349A (es)
CA (1) CA2380902C (es)
CZ (1) CZ294433B6 (es)
DE (1) DE60003438T2 (es)
DK (1) DK1212095T3 (es)
ES (1) ES2195925T3 (es)
HK (1) HK1044285A1 (es)
HU (1) HUP0202895A3 (es)
IE (1) IES990700A2 (es)
IL (1) IL148044A0 (es)
MX (1) MXPA02001415A (es)
NO (1) NO20020762L (es)
NZ (1) NZ517251A (es)
PL (1) PL199862B1 (es)
PT (1) PT1212095E (es)
RU (1) RU2211694C1 (es)
TW (1) TWI230069B (es)
WO (1) WO2001012232A2 (es)
ZA (1) ZA200202027B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
PT1204429E (pt) * 1999-08-18 2004-02-27 Conseils De Rec Appl Scient S Formulacao de libertacao prolongada de um peptido
EP1697035B1 (en) * 2003-12-22 2017-11-15 Warren H. Finlay Powder formation by atmospheric spray-freeze drying
RU2407751C2 (ru) 2004-10-27 2010-12-27 Юниверсити Оф Денвер Аналоги адренокортикотропного гормона и относящиеся к ним методы

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU220137B (hu) * 1993-01-06 2001-11-28 Kinerton Ltd. Biológiailag lebontható poliészterek és biológiailag aktív polipeptidek ionos molekuláris konjugátumai, eljárás ezek előállítására és eljárás mikrorészecskék előállítására
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
WO1995004752A1 (en) * 1993-08-09 1995-02-16 Biomeasure, Inc. Therapeutic peptide derivatives
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
AU3215597A (en) * 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
DE69907870T2 (de) 1998-01-29 2004-03-04 Kinerton Ltd., Blanchardstown Verfahren zur herstellung von absorbierbaren mikropartikeln
WO2000012232A1 (fr) 1998-08-28 2000-03-09 Mitutoyo Corporation Laveuse automatique de pieces pour intervention prealable dans un systeme de mesure et de production automatique equipe de ladite laveuse
PT1204429E (pt) 1999-08-18 2004-02-27 Conseils De Rec Appl Scient S Formulacao de libertacao prolongada de um peptido

Also Published As

Publication number Publication date
AU6464700A (en) 2001-03-13
RU2211694C1 (ru) 2003-09-10
DK1212095T3 (da) 2003-10-06
EP1212095B1 (en) 2003-06-18
WO2001012232A8 (en) 2002-06-06
CN1823736A (zh) 2006-08-30
PT1212095E (pt) 2003-10-31
EP1212095A2 (en) 2002-06-12
ES2195925T3 (es) 2003-12-16
BR0013349A (pt) 2002-04-23
JP2003507346A (ja) 2003-02-25
ZA200202027B (en) 2002-12-24
RU2002106809A (ru) 2004-01-20
IL148044A0 (en) 2002-09-12
WO2001012232A3 (en) 2002-04-04
ATE243044T1 (de) 2003-07-15
NO20020762L (no) 2002-04-16
HK1044285A1 (en) 2002-10-18
CN1246040C (zh) 2006-03-22
DE60003438D1 (de) 2003-07-24
WO2001012232A2 (en) 2001-02-22
HUP0202895A3 (en) 2003-11-28
AU755229B2 (en) 2002-12-05
MXPA02001415A (es) 2002-08-12
PL354263A1 (en) 2003-12-29
CZ2002266A3 (cs) 2002-05-15
NZ517251A (en) 2003-08-29
TWI230069B (en) 2005-04-01
JP3730917B2 (ja) 2006-01-05
US6893645B1 (en) 2005-05-17
CN1377283A (zh) 2002-10-30
IES990700A2 (en) 2001-08-22
CA2380902A1 (en) 2001-02-22
PL199862B1 (pl) 2008-11-28
CA2380902C (en) 2008-08-05
CZ294433B6 (cs) 2005-01-12
DE60003438T2 (de) 2004-05-06
NO20020762D0 (no) 2002-02-15
HUP0202895A2 (hu) 2003-02-28

Similar Documents

Publication Publication Date Title
TR200103474T2 (tr) Bileşimlerin anti-bakteriyel madde olarak yeni kullanımları
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
SE0100901D0 (sv) New composition
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
PT1193270E (pt) Pirrolobenzodiazepinas
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
BR0311261A (pt) Composição lìquida aquosa branqueadora dos dentes, e, método para branquear os dentes
TR200201461T2 (tr) Esterleştirme katalizör bileşikleri ve bunların kullanılması
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
RS52214B (en) HDAC INHIBITOR PHARMACEUTICAL FORMULATIONS
BRPI0416986A (pt) preparação farmacêutica compreendendo um anticorpo contra o receptor de egf
ES2191977T3 (es) Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.
AR079399A2 (es) Procedimientos para preparar bifenazato
GT200200069A (es) Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso
SE0201659D0 (sv) Modified release pharmaceutical formulation
ATE300541T1 (de) Pyrazolopyridinderivate
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
ATE333901T1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
AR035110A1 (es) Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto
AR022647A1 (es) Proceso para preparar una formulacion de liberacion sostenida
CY1105345T1 (el) Φαινυλαλκινια
SE9903290D0 (sv) Novel compounds
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
DK1180094T3 (da) Kondenserede polycykliske aminosyrer som farmaceutiske midler
DE60005517D1 (de) Kaliumkanal-blockierende mittel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal